Clinical Trial Update: Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating an anti-CD19 CAR-T cell therapy for ANCA-associated vasculitis, with recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis

Drugs mentioned

• Anti-CD19 CAR-T cell therapy (CD19-targeted chimeric antigen receptor T cells)

Snippet

Sponsor: David Simon | Conditions: ANCA-IgG-positive ANCA Associated Vasculitis | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING